Patient Preference With Visicol Tablet Preparation for Colonoscopy

Preparation for Colonoscopy Clinical Trial

Official title:

Patient Preference and Acceptance With Sodium Phosphate Tablet Preparation for Colonoscopy: A Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00318305
• Other study ID #: 392-05
• Status: Completed
• Phase: N/A
• First received: April 24, 2006
• Last updated: December 1, 2009
• Start date: March 2005
• Est. completion date: April 2006

Study information

• Verified date: December 2009
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine patient preference and acceptance of tablet sodium phosphate bowel preparation in patients who had polyethylene glycol (PEG) solution for their prior colonoscopy. This study will provide answers related to the patient preferences and their acceptance of this new method of bowel preparation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: April 2006
• Est. primary completion date: April 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Prior colonoscopy with PEG solution in the past one year

• Must be able to swallow tablets

Exclusion Criteria:

• Patients below 18 years and above 100 years.

• Congestive heart failure

• Chronic renal failure

• Pre-existing electrolyte disorder

• Pre-existing mega-colon or a motility disorder.

• Patients with pre-existing seizure disorder.

• Patients scheduled for colonoscopy after 1:00 p.m. will be excluded from the study.

• Pregnant or lactating women

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Preparation for Colonoscopy

Locations

Country	Name	City	State
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	InKine Pharmaceutical

Country where clinical trial is conducted

United States,